Ms. Julie Voss Profile

Julie Voss

at UT Health

SPIE Involvement:

Author

Publications (2)

SPIE Journal Paper | 9 December 2020 Open Access

Development of a drug–device combination for fluorescence-guided surgery in neuroendocrine tumors

Servando Hernandez Vargas, Christie Lin, Julie Voss, Sukhen Ghosh, Daniel Halperin, Solmaz Agha Amiri, Hop Tran Cao, Naruhiko Ikoma, Adam Uselmann, Ali Azhdarinia

JBO, Vol. 25, Issue 12, 126002, (December 2020) https://doi.org/10.1117/12.10.1117/1.JBO.25.12.126002

KEYWORDS: Tumors, Luminescence, Imaging systems, Tissues, Surgery, Visualization, In vivo imaging, Image quality, Lung, Imaging devices

Read Abstract +

Significance: The use of cancer-targeted contrast agents in fluorescence-guided surgery (FGS) has the potential to improve intraoperative visualization of tumors and surgical margins. However, evaluation of their translational potential is challenging. Aim: We examined the utility of a somatostatin receptor subtype-2 (SSTR2)-targeted fluorescent agent in combination with a benchtop near-infrared fluorescence (NIRF) imaging system to visualize mouse xenografts under conditions that simulate the clinical FGS workflow for open surgical procedures. Approach: The dual-labeled somatostatin analog, Ga67-MMC(IR800)-TOC, was injected into mice (n = 24) implanted with SSTR2-expressing tumors and imaged with the customized OnLume NIRF imaging system (Madison, Wisconsin). In vivo and ex vivo imaging were performed under ambient light. The optimal dose (0.2, 0.5, and 2 nmol) and imaging time point (3, 24, 48, and 72 h) were determined using contrast-to-noise ratio (CNR) as the image quality parameter. Video captures of tumor resections were obtained to provide an FGS readout that is representative of clinical utility. Finally, a log-transformed linear regression model was fitted to assess congruence between fluorescence readouts and the underlying drug distribution. Results: The drug–device combination provided high in vivo and ex vivo contrast (CNRs > 3, except lung at 3 h) at all time points with the optimal dose of 2 nmol. The optimal imaging time point was 24-h post-injection, where CNRs > 6.5 were achieved in tissues of interest (i.e., pancreas, small intestine, stomach, and lung). Intraoperative FGS showed excellent utility for examination of the tumor cavity pre- and post-resection. The relationship between fluorescence readouts and gamma counts was linear and strongly correlated (n = 334, R2 = 0.71; r = 0.84; P < 0.0001). Conclusion: The innovative OnLume NIRF imaging system enhanced the evaluation of Ga67-MMC(IR800)-TOC in tumor models. These components comprise a promising drug–device combination for FGS in patients with SSTR2-expressing tumors.

DOWNLOAD PAPER

Proceedings Article | 19 February 2020 Presentation + Paper

A proof-of-concept methodology to validate the in situ visualization of residual disease using cancer-targeted molecular agents in fluorescence-guided surgery

Servando Hernandez Vargas, Christie Lin, Solmaz AghaAmiri, Julie Voss, Naruhiko Ikoma, Hop Tran Cao, Sukhen Ghosh, Adam Uselmann, Ali Azhdarinia

Proceedings Volume 11222, 112220P (2020) https://doi.org/10.1117/12.2546190

KEYWORDS: Tumors, Luminescence, Surgery, Visualization, Imaging systems, Cancer, Tissues, Receptors, Optical inspection, Reflectivity

Read Abstract +

View contact details

UPDATE YOUR PROFILE

Is this your profile? Update it now.

Sign into your SPIE.org account

Don’t have a profile and want one?

Create an account on SPIE.org

Keywords/Phrases

Search In:

Publication Years